Impact of viral dose and major histocompatibility complex class IB haplotype on viral outcome in mauritian cynomolgus monkeys vaccinated with Tat upon challenge with simian/human immunodeficiency virus SHIV89.6P
- PMID: 20554774
- PMCID: PMC2919029
- DOI: 10.1128/JVI.00377-10
Impact of viral dose and major histocompatibility complex class IB haplotype on viral outcome in mauritian cynomolgus monkeys vaccinated with Tat upon challenge with simian/human immunodeficiency virus SHIV89.6P
Abstract
The effects of the challenge dose and major histocompatibility complex (MHC) class IB alleles were analyzed in 112 Mauritian cynomolgus monkeys vaccinated (n = 67) or not vaccinated (n = 45) with Tat and challenged with simian/human immunodeficiency virus (SHIV) 89.6P(cy243.) In the controls, the challenge dose (10 to 20 50% monkey infectious doses [MID(50)]) or MHC did not affect susceptibility to infection, peak viral load, or acute CD4 T-cell loss, whereas in the chronic phase of infection, the H1 haplotype correlated with a high viral load (P = 0.0280) and CD4 loss (P = 0.0343). Vaccination reduced the rate of infection acquisition at 10 MID(50) (P < 0.0001), and contained acute CD4 loss at 15 MID(50) (P = 0.0099). Haplotypes H2 and H6 were correlated with increased susceptibility (P = 0.0199) and resistance (P = 0.0087) to infection, respectively. Vaccination also contained CD4 depletion (P = 0.0391) during chronic infection, independently of the challenge dose or haplotype.
Figures

Similar articles
-
Containment of infection in tat vaccinated monkeys after rechallenge with a higher dose of SHIV89.6P(cy243).Viral Immunol. 2009 Apr;22(2):117-24. doi: 10.1089/vim.2008.0082. Viral Immunol. 2009. PMID: 19326998
-
Comparative study of Tat vaccine regimens in Mauritian cynomolgus and Indian rhesus macaques: influence of Mauritian MHC haplotypes on susceptibility/resistance to SHIV(89.6P) infection.Vaccine. 2008 Jun 19;26(26):3312-21. doi: 10.1016/j.vaccine.2008.03.100. Epub 2008 Apr 30. Vaccine. 2008. PMID: 18486283 Free PMC article.
-
Vectored Gag and Env but not Tat show efficacy against simian-human immunodeficiency virus 89.6P challenge in Mamu-A*01-negative rhesus monkeys.J Virol. 2005 Oct;79(19):12321-31. doi: 10.1128/JVI.79.19.12321-12331.2005. J Virol. 2005. PMID: 16160159 Free PMC article.
-
Tat protein vaccination of cynomolgus macaques influences SHIV-89.6P cy243 epitope variability.Virus Genes. 2008 Feb;36(1):105-15. doi: 10.1007/s11262-007-0179-8. Epub 2007 Nov 30. Virus Genes. 2008. PMID: 18049888
-
Protection of neonatal macaques against experimental SHIV infection by human neutralizing monoclonal antibodies.Transfus Clin Biol. 2001 Aug;8(4):350-8. doi: 10.1016/s1246-7820(01)00187-2. Transfus Clin Biol. 2001. PMID: 11642027 Review.
Cited by
-
Role of HIV-1 Tat Protein Interactions with Host Receptors in HIV Infection and Pathogenesis.Int J Mol Sci. 2024 Jan 30;25(3):1704. doi: 10.3390/ijms25031704. Int J Mol Sci. 2024. PMID: 38338977 Free PMC article. Review.
-
Multilocus definition of MHC haplotypes in pedigreed cynomolgus macaques (Macaca fascicularis).Immunogenetics. 2012 Oct;64(10):755-65. doi: 10.1007/s00251-012-0632-2. Epub 2012 Jul 8. Immunogenetics. 2012. PMID: 22772814 Free PMC article.
-
Anti-Tat Immunity in HIV-1 Infection: Effects of Naturally Occurring and Vaccine-Induced Antibodies Against Tat on the Course of the Disease.Vaccines (Basel). 2019 Aug 26;7(3):99. doi: 10.3390/vaccines7030099. Vaccines (Basel). 2019. PMID: 31454973 Free PMC article. Review.
-
Variable prevalence and functional diversity of the antiretroviral restriction factor TRIMCyp in Macaca fascicularis.J Virol. 2011 Oct;85(19):9956-63. doi: 10.1128/JVI.00097-11. Epub 2011 Jul 27. J Virol. 2011. PMID: 21795330 Free PMC article.
-
New insights into pathogenesis point to HIV-1 Tat as a key vaccine target.Arch Virol. 2021 Nov;166(11):2955-2974. doi: 10.1007/s00705-021-05158-z. Epub 2021 Aug 14. Arch Virol. 2021. PMID: 34390393 Free PMC article. Review.
References
-
- Anastassopoulou, C. G., and L. G. Kostrikis. 2003. The impact of human allelic variation on HIV-1 disease. Curr. HIV Res. 1:185-203. - PubMed
-
- Bellino, S., V. Francavilla, O. Longo, A. Tripiciano, G. Paniccia, A. Arancio, V. Fiorelli, A. Scoglio, B. Collacchi, M. Campagna, A. Lazzarin, G. Tambussi, C. T. Din, R. Visintini, P. Narciso, A. Antinori, G. D'Offizi, M. Giulianelli, M. Carta, A. Di Carlo, G. Palamara, M. Giuliani, M. E. Laguardia, P. Monini, M. Magnani, F. Ensoli, and B. Ensoli. 2009. Parallel conduction of the phase I preventive and therapeutic trials based on the Tat vaccine candidate. Rev. Recent Clin. Trials 4:195-204. - PubMed
-
- Borsetti, A., S. Baroncelli, M. T. Maggiorella, S. Bellino, S. Moretti, L. Sernicola, R. Belli, B. Ridolfi, S. Farcomeni, D. R. Negri, A. Cafaro, B. Ensoli, and F. Titti. 2008. Viral outcome of simian-human immunodeficiency virus SHIV-89.6P adapted to cynomolgus monkeys. Arch. Virol. 153:463-472. - PubMed
-
- Cafaro, A., A. Caputo, C. Fracasso, M. T. Maggiorella, D. Goletti, S. Baroncelli, M. Pace, L. Sernicola, M. L. Koanga-Mogtomo, M. Betti, A. Borsetti, R. Belli, L. Akerblom, F. Corrias, S. Butto, J. Heeney, P. Verani, F. Titti, and B. Ensoli. 1999. Control of SHIV-89.6P-infection of cynomolgus monkeys by HIV-1 Tat protein vaccine. Nat. Med. 5:643-650. - PubMed
-
- Cafaro, A., A. Caputo, M. T. Maggiorella, S. Baroncelli, C. Fracasso, M. Pace, A. Borsetti, L. Sernicola, D. R. Negri, P. ten Haaft, M. Betti, Z. Michelini, I. Macchia, E. Fanales-Belasio, R. Belli, F. Corrias, S. Butto, P. Verani, F. Titti, and B. Ensoli. 2000. SHIV89.6P pathogenicity in cynomolgus monkeys and control of viral replication and disease onset by human immunodeficiency virus type 1 Tat vaccine. J. Med. Primatol. 29:193-208. - PubMed
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Research Materials